Journal
GENES & DEVELOPMENT
Volume 16, Issue 16, Pages 2045-2057Publisher
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.993902
Keywords
Ras; RalGEF; transformation; tumorigenesis; human
Categories
Funding
- NCI NIH HHS [R01 CA082481, R01 CA094184, CA82481, CA094184, CA69577, R01 CA069577] Funding Source: Medline
- NINDS NIH HHS [NS02055] Funding Source: Medline
Ask authors/readers for more resources
The spectrum of tumors associated with oncogenic Ras in humans often differs from those in mice either treated with carcinogens or engineered to sporadically express oncogenic Ras, suggesting that the mechanism of Ras transformation may be different in humans. Ras stimulates primarily three main classes of effector proteins, Rafs, PI3-kinase, and Ra1GEFS, with Raf generally being the most potent at transforming murine cells. Using oncogenic Ras mutants that activate single effectors as well as constitutively active effectors, we find that the Ra1GEF, and not the Raf or PI3-kinase pathway, is sufficient for Ras transformation in human cells. Thus, oncogenic Ras may transform murine and human cells by distinct mechanisms, and the Ra1GEF pathway-previously deemed to play a secondary role in Ras transformation-could represent a new target for anti-cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available